Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers
NCT02182401 · Boehringer Ingelheim · PHASE1 · terminated · last registry update 2014-07-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Boehringer Ingelheim |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABRA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-04-13Results posted on the registry: Medical University of South Carolina, Acamprosate (NCT00330174)
- 2015-03-02Phase 3 first posted: Hannover Medical School, Phenobarbital + Phenytoin (NCT02374567)
- 2014-12-30Results posted on the registry: University of New Mexico, Ketamine + Methohexital (NCT01567852)
- 2014-12-18Results posted on the registry: State University of New York - Upstate Medical University, Acamprosate (NCT00591565)
- 2013-12-31Results posted on the registry: University of Pennsylvania, acamprosate + placebo (NCT00385268)
- 2013-08-30Results posted on the registry: James Murrough, Ketamine + Methohexital (NCT01309581)
- 2013-08-30Also stopped (terminated): James Murrough, Ketamine + Methohexital (NCT01309581)
- 2013-08-06Results posted on the registry: Mayo Clinic, Ketamine + methohexital (NCT01367119)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision